TARRYTOWN, N.Y.--(BUSINESS WIRE)--PsychoGenics Inc., and Roche, Basel, Switzerland, have entered into a drug discovery and development agreement in which they combine their complementary strengths and expertise to identify a new generation of treatments for neuropsychiatric disorders.
The agreement provides that Roche will provide drug candidates and PsychoGenics will evaluate these candidates, using its proprietary drug discovery technologies, for the treatment of neuropsychiatric disorders. Either party has the option to exclusively develop any drug candidate emerging from this collaboration, with the non-developing party receiving milestones and royalties commensurate with the stage of development.
Dr. Emer Leahy, President and CEO of PsychoGenics said, “We are delighted to enter into this agreement which expands our relationship with Roche and complements Roche’s own discovery efforts. We are confident, given our successes with other partners to date, that our proprietary and comprehensive approach can identify unexploited commercial potential for Roche compounds.”
PsychoGenics’ technologies combine its broad in vivo behavioral expertise together with recent developments in robotics, computer vision and bio/cheminformatics to evaluate drug candidates for potential utility across the spectrum of neuropsychiatric disease indications. Working in partnership with pharmaceutical and biotech companies, PsychoGenics has been instrumental in identifying therapeutic potential for discontinued compounds as well as early stage compounds including some with novel “first-in-class” mechanisms of action.
About PsychoGenics
PsychoGenics is a leader in preclinical behavioral neurobiology. The Company applies its behavioral expertise together with advances in robotics, computer vision, and informatics to provide innovative solutions for central nervous system drug discovery. PsychoGenics works with pharmaceutical and biotechnology companies, academic institutions and not-for-profit research foundations to help discover treatments for such major neurological and psychiatric disorders as: ALS, anxiety, cognitive impairment, depression, Huntington’s Disease, psychosis/schizophrenia, and SMA. The Company’s in house discovery efforts have focused on psychiatric indications.
Contacts
PsychoGenics Inc. David Pushett, Ph.D., 914-593-0640 V.P., Business Development www.psychogenics.com
